Overview

Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas

Status:
Not yet recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
To determine the utility of tissue plasminogen activator (tPA) in the clearance of chronic subdural hematomas (CSDH). Intra-catheter tPA will be administered during surgical procedure and allowed to break down blood clot to assist with removal/drainage during twist drill craniostomy procedure.
Phase:
Phase 4
Details
Lead Sponsor:
Hamilton Health Sciences Corporation
Treatments:
Plasminogen
Tissue Plasminogen Activator